| CRISPR Therapeutics–SEVERAL: investment, 201911 public offering up to $315.25m with 4.25m+637.5k common shares at $64.5/share |
2019-11-19 |
| Bluebird Bio–Forty Seven: gene therapy, 201911– collab research using Ab-based conditioing regimen with LVV HSC gene therapy |
2019-11-12 |
| Celgene–Editas Medicine: T cell therapy, 201911– collab expansion T cell medicines for cancer + autoimmune diseases incl $70m milestone payment |
2019-11-12 |
| Immatics–Genedata: bioinformatics, 201911– license to Genedata Biologics for use with Xceptor TCR discovery + engineering platform |
2019-11-12 |
| Clear Genetics–Invitae: investment, 201911 acquisition $50m with $25m cash + $25m shares of Clear Genetics by Invitae |
2019-11-11 |
| Expedeon–Abcam: investment, 201911– acquisition €120m cash of immunology + proteomics business of Expedeon by Abcam ANNOUNCED |
2019-11-11 |
| eGenesis–Alta Partners: investment, 201911 financing round Series B totalling $100m incl existing + co-investor Alta Partners |
2019-11-07 |
| eGenesis–ARCH Venture: investment, 201911 financing round Series B totalling $100m incl existing + co-investor ARCH Venture Partners |
2019-11-07 |
| eGenesis–Bayer: investment, 201911 financing round Series B totalling $100m incl new + co-investor Leaps by Bayer |
2019-11-07 |
| eGenesis–Biomatics Capital: investment, 201911 financing round Series B totalling $100m incl existing + co-investor Biomatics Capital |
2019-11-07 |
| eGenesis–Fresenius: investment, 201911 financing round Series B totalling $100m incl lead investor Fresenius Medical Care Ventures |
2019-11-07 |
| eGenesis–Khosla Ventures: investment, 201911 financing round Series B totalling $100m incl existing + co-investor Khosla Ventures |
2019-11-07 |
| eGenesis–SEVERAL: investment, 201911 financing round Series B $100m led by Fresenius Medical Care Ventures |
2019-11-07 |
| eGenesis–Wellington Partners: investment, 201911 financing round Series B totalling $100m incl new + co-investor Wellington Partners |
2019-11-07 |
| Owlstone–Thermo Fisher: mass spectrometry, 201911– collab integration of Q Exactive GC Hybrid Quad-Orbitrap MS into Breath Biopsy platform |
2019-11-07 |
| Argenx–SEVERAL: investment, 201911 global offering $557m with 4.6m ordinary shares incl in the form of ADSs |
2019-11-06 |
| Artios Pharma–Univ Texas: ATR inhibitors, 201911– license excl ww to small-molecula ATR inhibitor programme from MD Anderson + ShangPharma Innovation |
2019-11-06 |
| Greenough–KDM Communications: investment, 201911 merger combination to provide transatlantic PR services |
2019-11-06 |
| OTHER–Ervaxx: cancer immunotherapy, 201911 collab existent strategic r+d partnership with undisclosed leading global pharma company |
2019-11-06 |
| Rentschler–General Electric: single-use bioreactor, 201911–202006 supply Xcellerex XDR-500 bioreactor for Rentschler facility in Milford, MA |
2019-11-06 |
| Pieris–BVF Partners: investment, 201911 private placement totalling $32m incl existing + lead investor BVF Partners |
2019-11-04 |
| Pieris–SEVERAL: investment, 201911 private placement $32m w 9.015m units (shares + warrants) at $3.55/unit led by BVF Partners |
2019-11-04 |
| Fitbit–Alphabet: investment, 201911– acquisition of Fibit Inc by Google LLC for $7.35/share in cash valuing Fibtit at $2.1b ANNOUNCED |
2019-11-01 |
| BeiGene–Amgen: cancer drugs, 201910– collab strategic alliance incl Xgeva + Kyprolis + Blincyto + 20 other assets dev + commerc in China |
2019-10-31 |
| BeiGene–Amgen: investment, 201910 acquisition 20.5% stake in BeiGene for $2.7b in cash by Amgen in connnection w strategic alliance |
2019-10-31 |
| Gyros–Mesa Labs: investment, 201910 acquisition $180m in cash of Gyros Protein Technologies Holding AB by Mesa Laboratories Inc |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition 10% stake in Roivant by Sumitomo Dainippon Pharma in connection w strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Altavant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Enzyvant Therapeutics by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Myovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Spirovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Urovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Sumitomo–Roivant: drug development, 201910– collab strategic alliance $3b upfront incl transfer of 5 vants to Sumitomo Dainippon Pharma |
2019-10-31 |
| Tmunity Therapeutics–American Cancer Society: investment, 201910 financing round Series B totalling $75m incl co-investor BrightEdge fund of ACS |
2019-10-31 |
| Tmunity Therapeutics–Andreessen Horowitz: investment, 201910 financing round Series B totalling $75m incl lead investor Andreessen Horowitz |
2019-10-31 |
| Tmunity Therapeutics–Be The Match: investment, 201910 financing round Series B totalling $75m incl co-investor Be The Match BioTherapies |
2019-10-31 |
| Tmunity Therapeutics–Gilead Sciences: investment, 201910 financing round Series B totalling $75m incl co-investor Gilead Sciences |
2019-10-31 |
| Tmunity Therapeutics–Sam Brown: public relations, 201910 service existent by Sam Brown Inc |
2019-10-31 |
| Tmunity Therapeutics–SEVERAL: investment, 201910 financing round Series B $75m led by Andreessen Horowitz |
2019-10-31 |
| Tmunity Therapeutics–Univ Pennsylvania: investment, 201910 financing round Series B totalling $75m incl co-investor Univ Pennsylvania |
2019-10-31 |
| Tmunity Therapeutics–Westlake Village BioPartners: investment, 201910 financing round Series B totalling $75m incl co-investor Westlake Village BP |
2019-10-31 |
| genOway–Institut Pasteur: transgenic anmials, 201910– license extension from IP + Cellectis to genOway to take legal actions against infringement |
2019-10-30 |
| Disc Medicine–AbbVie: therapeutics antibodies, 201910– license €na ww excl to series of hemojuvelin antagonist MAbs from AbbVie |
2019-10-29 |
| Disc Medicine–Access Industries: investment, 201910 financing round Series A totalling $50m incl new + co-investor Access Biotechnology |
2019-10-29 |
| Disc Medicine–Atlas Venture: investment, 201910 financing round Series A totalling $50m incl existing + co-investor Atlas Venture |
2019-10-29 |
| Disc Medicine–Novo Group: investment, 201910 financing round Series A totalling $50m incl new + lead investor Novo Holdings A/S |
2019-10-29 |
| Disc Medicine–SEVERAL: investment, 201910 financing round Series A $50m led by Novo Holdings A/S |
2019-10-29 |
| Phathom Pharmaceuticals–Sam Brown: public relations, 201910 service existent by Sam Brown Inc |
2019-10-29 |
| Phathom Pharmaceuticals–SEVERAL: investment, 201910 IPO $181.7m+$27.2m with 9.56m+1.43m shares common stock at $19/share at Nasdaq Global Select |
2019-10-29 |
| TherapeuticsMD–SEVERAL: investment, 201910 underwritten public offering $82.225m net $77m with 29.9m shares common stock at $2.75/share |
2019-10-29 |
| Centogene–SEVERAL: investment, 201910–201911 IPO $56m+$8.4m with 4m+600k comon shares at $14/share at Nasdaq Global Market |
2019-10-28 |
| i-Dositecno–SP Industries: investment, 201910 acquisition of assets of i-Dositecno by SP Industries |
2019-10-28 |
| PierianDx–SEVERAL: investment, 201910 financing round Series B $27m co-led by ATW Partners + SJF Ventures |
2019-10-28 |
| SMS-Oncology–Cato Research: investment, 201910 merger €na |
2019-10-28 |
| OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m |
2019-10-23 |
| Brii Biosciences–Qpex Biopharma: antibiotics, 201910– collab developm + comercialisation in Greater China |
2019-10-22 |
| Encycle Therapeutics–Zealand Pharma: investment, 201910 acquisition of Encycle Therapeutics for up to $80m |
2019-10-22 |
| MCG Motion Capture–Akampion: public relations, 201910 service existent by Akampion |
2019-10-22 |
| MCG Motion Capture–Biotech Alliances International: investment banking, 201910– service excl for planned $15m Series A Round of MCG |
2019-10-22 |
| MCG Motion Capture–SEVERAL: investment, 201910– PLANNED financing round Series A $15m |
2019-10-22 |
| Arcutis Biotherapeutics–Bain Capital: investment, 201910 financing round Series C totalling $94.5m incl existing + co-investor Bain Capital LS |
2019-10-21 |
| Arcutis Biotherapeutics–BlackRock: investment, 201910 financing round Series C totalling $94.5m incl new + co-investor funds managed by BlackRock |
2019-10-21 |
| Arcutis Biotherapeutics–Frazier: investment, 201910 financing round Series C totalling $94.5m incl existing + co-investor Frazier Healthcare Partners |
2019-10-21 |
| Arcutis Biotherapeutics–Goldman Sachs: investment, 201910 financing round Series C totalling $94.5m incl new + co-investor Goldman Sachs |
2019-10-21 |
| Arcutis Biotherapeutics–HBM: investment, 201910 financing round Series C totalling $94.5m incl new + lead investor HBM Healthcare Investments |
2019-10-21 |
| Arcutis Biotherapeutics–Nan Fung: investment, 201910 financing round Series C totalling $94.5m incl new + co-investor Pivotal BioVentures |
2019-10-21 |
| Arcutis Biotherapeutics–Omega Advisors: investment, 201910 financing round Series C totalling $94.5m incl new + co-investor Omega Funds |
2019-10-21 |
| Arcutis Biotherapeutics–OrbiMed: investment, 201910 financing round Series C totalling $94.5m incl existing + co-investor OrbiMed |
2019-10-21 |
| Arcutis Biotherapeutics–RA Capital Management: investment, 201910 financing round Series C totalling $94.5m incl existing + co-investor RA Capital |
2019-10-21 |
| Arcutis Biotherapeutics–SEVERAL: investment, 201910 financing round Series C $94.5m led by HBM Healthcare Investments |
2019-10-21 |
| Arcutis Biotherapeutics–Vivo Capital: investment, 201910 financing round Series C totalling $94.5m incl new + co-investor Vivo Capital |
2019-10-21 |
| Bavarian Nordic–GSK: vaccines, 201910 acquisition up to €796m incl €301m upfront of manufacturing + global rights to Rabipur/RabAvert + Encepur by BN |
2019-10-21 |
| Danaher–Sartorius: investment, 201910– acquisition $750m three life science businesses by Sartorius part of regulatory clearance for GE/Danaher deal |
2019-10-21 |
| Innate Pharma–SEVERAL: investment, 201910 pirvate placement €22.13m with 4.45m ordinary shares at €4.97/share |
2019-10-21 |
| Verseau Therapeutics–20/20 HealthCare Partners: investment, 201910 launch with a total financing of $50m incl investor 20/20 HealthCare Partners |
2019-10-21 |
| Verseau Therapeutics–Alexandria Real Estate: investment, 201910 launch with a total financing of $50m incl investor Alexandria Venture Investments |
2019-10-21 |
| Verseau Therapeutics–Highlight Capital: investment, 201910 launch with a total financing of $50m incl investor Highlight Capital |
2019-10-21 |
| Verseau Therapeutics–InHarv Partners: investment, 201910 launch with a total financing of $50m incl investor InHarv Partners |
2019-10-21 |
| Verseau Therapeutics–Mark Foundation: investment, 201910 launch with a total financing of $50m incl The Mark Foundation for Cancer Research |
2019-10-21 |
| Verseau Therapeutics–SEVERAL: investment, 201910 launch with $50m financing from 20/20 HealthCare Partners + 3SBio + Alexandria Venture et al |
2019-10-21 |
| Verseau Therapeutics–Yonghua Capital: investment, 201910 launch with a total financing of $50m incl investor Yonghua Capital |
2019-10-21 |
| Plexium–Column Group: investment, 201910 financing round Series A totalling $28m incl co-lead investor The Column Group |
2019-10-17 |
| Plexium–CRV: investment, 201910 financing round Series A totalling $28m incl co-investor CRV |
2019-10-17 |
| Plexium–DCVC: investment, 201910 financing round Series A totalling $28m incl co-lead investor DCVC Bio |
2019-10-17 |
| Plexium–Little Dog Communications: public relations, 201910 service existent by Little Dog |
2019-10-17 |
| Plexium–Merck (DE): investment, 201910 financing round Series A totalling $28m incl co-investor M Ventures |
2019-10-17 |
| Plexium–Neotribe Ventures: investment, 201910 financing round Series A totalling $28m incl co-investor Neotribe Ventures |
2019-10-17 |
| Plexium–SEVERAL: investment, 201910 financing round Series A $28m co-led by DCVC Bio + The Column Group |
2019-10-17 |
| Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund |
2019-10-17 |
| Healx–Atomico: investment, 201910 financing round Series B totalling $56m incl new + lead investor Atomico |
2019-10-16 |
| Healx–Global Brain: investment, 201910 financing round Series B totalling $56m incl new + co-investor Global Brain |
2019-10-16 |
| Healx–Intel: investment, 201910 financing round Series B totalling $56m incl new + co-investor Intel Capital |
2019-10-16 |
| Healx–SEVERAL: investment, 201910 financing round Series B $56m led by new investor Atomico |
2019-10-16 |
| Waters–Salesforce: CRM cloud software, 201910– supply Waters to use Sales Cloud Einstein + Service Cloud + Einstein Analytics |
2019-10-16 |
| CRISPR Therapeutics–KSQ Therapeutics: CRISPR-based cell therapy, 201910– cross-licensing €na genome editing + CAR-T cell therapy IP |
2019-10-15 |
| Editas Medicine–AskBio: AAV technology, 201910– strategic research collab in vivo delivery of genome editing medicines with AAV |
2019-10-15 |
| FloDesign Sonics–Merck (DE): investment, 201910 acquisition €na by Merck |
2019-10-10 |
| Mission Bio–VSC (US): public relations, 201910 service existent by VSC |
2019-10-10 |
| Ra Pharmaceuticals–UCB: investment, 201910– acquisition $2.5b in cash for $48/share incl acquired net cash of $315m ANNOUNCED |
2019-10-10 |
| Celmatix–Evotec: drug discovery services, 201910– collab €na developm pre-clinical programs for reproductive women’s health |
2019-10-09 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
